Suppr超能文献

大鼠胚胎干细胞的分离培养和蛋白酶激活受体-2 基因敲除大鼠的构建。

Derivation of rat embryonic stem cells and generation of protease-activated receptor-2 knockout rats.

机构信息

Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka-higashi, Fujisawa City, Kanagawa 251-8555, Japan.

出版信息

Transgenic Res. 2012 Aug;21(4):743-55. doi: 10.1007/s11248-011-9564-0. Epub 2011 Oct 15.

Abstract

One of the remarkable achievements in knockout (KO) rat production reported during the period 2008-2010 is the derivation of authentic embryonic stem (ES) cells from rat blastocysts using a novel culture medium containing glycogen synthase kinase 3 and mitogen-activated protein kinase kinase inhibitors (2i medium). Here, we report gene-targeting technology via homologous recombination in rat ES cells, demonstrating its use through production of a protease-activated receptor-2 gene (Par-2) KO rat. We began by generating germline-competent ES cells from Dark Agouti rats using 2i medium. These ES cells, which differentiate into cardiomyocytes in vitro, can produce chimeras with high ES cell contribution when injected into blastocysts. We then introduced a targeting vector with a neomycin-resistant gene driven by the CAG promoter to disrupt Par-2. After a 7-day drug selection, 489 neomycin-resistant colonies were obtained. Following screening by polymerase chain reaction (PCR) genotyping and quantitative PCR analysis, we confirmed three homologous recombinant clones, resulting in chimeras that transmitted the Par-2 targeted allele to offspring. Par-2 KO rats showed a loss of Par-2 messenger RNA expression in their stomach cells and a lack of PAR-2 mediated smooth muscle relaxation in the aorta as indicated by pharmacological testing. Compared with mice, rats offer many advantages in biomedical research, including a larger body size; consequently, they are widely used in scientific investigation. Thus, the establishment of a gene-targeting technology using rat ES cells will be a valuable tool in human disease model production and drug discovery.

摘要

在 2008 年至 2010 年期间,敲除(KO)大鼠生产方面的一项显著成就是利用含有糖原合成酶激酶 3 和丝裂原活化蛋白激酶激酶抑制剂(2i 培养基)的新型培养基从大鼠囊胚中获得真正的胚胎干细胞(ES 细胞)。在这里,我们通过同源重组在大鼠 ES 细胞中报告基因靶向技术,通过生产蛋白酶激活受体-2 基因(Par-2)KO 大鼠来证明其用途。我们首先使用 2i 培养基从黑腹大鼠中生成种系相容的 ES 细胞。这些 ES 细胞在体外分化为心肌细胞,当注入囊胚时可以产生具有高 ES 细胞贡献的嵌合体。然后,我们引入了一个靶向载体,该载体带有由 CAG 启动子驱动的新霉素抗性基因,以破坏 Par-2。经过 7 天的药物选择,获得了 489 个新霉素抗性菌落。通过聚合酶链反应(PCR)基因分型和定量 PCR 分析筛选后,我们确认了三个同源重组克隆,导致将 Par-2 靶向等位基因传递给后代的嵌合体。Par-2 KO 大鼠在其胃细胞中表现出 Par-2 信使 RNA 表达缺失,并且在药理学测试中缺乏 PAR-2 介导的主动脉平滑肌松弛。与小鼠相比,大鼠在生物医学研究中具有许多优势,包括体型较大;因此,它们被广泛用于科学研究。因此,使用大鼠 ES 细胞建立基因靶向技术将是生产人类疾病模型和药物发现的有价值的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验